BR112015002522A2 - cepa do micro-organismo esherichia coli produtora de pdna pcmv-vegf165, método de armazenamento de pdna, composição farmacêutica para a estimulação da angiogênese e método de aplicação. - Google Patents

cepa do micro-organismo esherichia coli produtora de pdna pcmv-vegf165, método de armazenamento de pdna, composição farmacêutica para a estimulação da angiogênese e método de aplicação.

Info

Publication number
BR112015002522A2
BR112015002522A2 BR112015002522A BR112015002522A BR112015002522A2 BR 112015002522 A2 BR112015002522 A2 BR 112015002522A2 BR 112015002522 A BR112015002522 A BR 112015002522A BR 112015002522 A BR112015002522 A BR 112015002522A BR 112015002522 A2 BR112015002522 A2 BR 112015002522A2
Authority
BR
Brazil
Prior art keywords
pdna
vegf165
pcmv
strain
producing
Prior art date
Application number
BR112015002522A
Other languages
English (en)
Other versions
BR112015002522B1 (pt
Inventor
Aleksandrovich ISAEV Artur
Ivanovich Vorob'ev Ivan
Aleksandrovna Orlova Nadezhda
Vadimovich Deev Roman
L'vovich Kiselev Sergej
Original Assignee
Nextgen Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextgen Company Ltd filed Critical Nextgen Company Ltd
Publication of BR112015002522A2 publication Critical patent/BR112015002522A2/pt
Publication of BR112015002522B1 publication Critical patent/BR112015002522B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112015002522-6A 2012-08-31 2013-08-02 Composição farmacêutica para estimulação da angiogênese BR112015002522B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012137126/10A RU2542385C2 (ru) 2012-08-31 2012-08-31 Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
RU2012137126 2012-08-31
PCT/RU2013/000669 WO2014035289A1 (en) 2012-08-31 2013-08-02 A pharmaceutical composition for stimulation of angiogenesis

Publications (2)

Publication Number Publication Date
BR112015002522A2 true BR112015002522A2 (pt) 2017-11-07
BR112015002522B1 BR112015002522B1 (pt) 2022-04-05

Family

ID=50183970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002522-6A BR112015002522B1 (pt) 2012-08-31 2013-08-02 Composição farmacêutica para estimulação da angiogênese

Country Status (13)

Country Link
US (1) US9616103B2 (pt)
EP (1) EP2890777B1 (pt)
CN (1) CN105308173B (pt)
BR (1) BR112015002522B1 (pt)
CA (1) CA2881799C (pt)
ES (1) ES2621675T3 (pt)
HU (1) HUE032520T2 (pt)
MX (1) MX360980B (pt)
PL (1) PL2890777T3 (pt)
RU (1) RU2542385C2 (pt)
SI (1) SI2890777T1 (pt)
WO (1) WO2014035289A1 (pt)
ZA (1) ZA201500909B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2558294C1 (ru) * 2014-09-16 2015-07-27 Общество с ограниченной ответственностью "НекстГен" Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
RU2694826C1 (ru) * 2018-06-05 2019-07-17 Юрий Валентинович Червяков Способ лечения хронической ишемии нижних конечностей атеросклеротического генеза при окклюзии артерий голени
US20210302340A1 (en) * 2018-08-08 2021-09-30 Justin L. Neill Methods and Apparatus for Low-Volatility Sampling
CN110760542B (zh) * 2019-11-18 2022-07-26 天津大学 一种共表达znf580和vegf165双基因的质粒及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742365B2 (en) * 1997-03-14 2002-01-03 Selective Genetics, Inc. Adenoviral vectors with modified tropism
US6627436B2 (en) * 1997-10-31 2003-09-30 Stratagene Vector for gene expression in prokaryotic and eukaryotic systems
WO1999045966A1 (en) * 1998-03-13 1999-09-16 American Home Products Corporation Polynucleotide composition, method of preparation, and use thereof
WO2000047235A2 (en) * 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7288521B2 (en) 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
CN1351055A (zh) 2000-10-26 2002-05-29 上海博德基因开发有限公司 一种新的多肽——人的血管内皮生长因子165受体(vegf－165r)10.67和编码这种多肽的多核苷酸
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
CN100431611C (zh) 2002-07-04 2008-11-12 朱静亚 多肽－脂质体与人血管内皮生长因子基因重组质粒复合物及用途
CN1717254A (zh) * 2002-12-02 2006-01-04 安增子摩祺株式会社 用于治疗或预防血管生成－依赖性症状的组合物
EA011554B1 (ru) * 2004-09-17 2009-04-28 Сентелион Стабильные жидкие композиции плазмидной днк
RU2297848C2 (ru) * 2005-05-11 2007-04-27 Александр Веньяминович Иткес Генно-инженерная конструкция vegf-ибмед (vegf-ibmed)
ES2338400B1 (es) 2008-05-06 2011-09-14 David Benet Ferrus Conjunto de moleculas antiangiogenicas y su uso.
US8367350B2 (en) * 2009-04-29 2013-02-05 Morehouse School Of Medicine Compositions and methods for diagnosis, prognosis and management of malaria

Also Published As

Publication number Publication date
HUE032520T2 (en) 2017-10-30
US9616103B2 (en) 2017-04-11
US20150335711A1 (en) 2015-11-26
BR112015002522B1 (pt) 2022-04-05
CA2881799C (en) 2019-10-29
CN105308173A (zh) 2016-02-03
WO2014035289A1 (en) 2014-03-06
MX360980B (es) 2018-11-22
WO2014035289A9 (en) 2014-05-08
EP2890777A1 (en) 2015-07-08
CA2881799A1 (en) 2014-03-06
ZA201500909B (en) 2016-10-26
PL2890777T3 (pl) 2017-07-31
EP2890777A4 (en) 2015-12-16
MX2015002658A (es) 2015-09-25
SI2890777T1 (sl) 2017-06-30
RU2012137126A (ru) 2014-03-10
RU2542385C2 (ru) 2015-02-20
CN105308173B (zh) 2020-03-17
EP2890777B1 (en) 2017-01-11
ES2621675T3 (es) 2017-07-04

Similar Documents

Publication Publication Date Title
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
CL2014000467A1 (es) Formulación que comprende cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados; metodo para obtener sustancia efectiva como plaguicida derivada de la formulación antes indicada.
PL3214081T3 (pl) Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
EP3130354A4 (en) Posaconazole pharmaceutical composition and preparation method, application and pharmaceutical preparation thereof
CL2013001850A1 (es) Composicion que contiene bacterias que comprenden una mutuacion sobre el gen swra, y metodo para mejorar elcrecimiento de las plantas , promover la salud o controlar enfermedades que las afecten basado en la aplicacion de dicha composicion.
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
DK3146515T3 (da) System og fremgangsmåde til lægemiddelopbevaring, -udlevering og -administration
BR112014025726A2 (pt) mecanismo, sistema e método para tratamento endodôntico
BR112013030521A2 (pt) preparação líquida para proteção biológica de plantas, método para a produção da mesma e respectiva utilização.
DK2924052T3 (da) Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
EP3287463A4 (en) Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
EP3440579A4 (en) INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES
BR112016025659A2 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
BR112014026149A2 (pt) método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
HK1205118A1 (zh) 環烷基甲酸類衍生物、其製備方法及其在醫藥上的應用
BR112013018884A2 (pt) método para o tratamento de biomassa com um sistema de torrefação, e, sistema de torrefação para o tratamento de biomassa.
BR112015002522A2 (pt) cepa do micro-organismo esherichia coli produtora de pdna pcmv-vegf165, método de armazenamento de pdna, composição farmacêutica para a estimulação da angiogênese e método de aplicação.
AP2015008599A0 (en) Pharmaceutical composition for treating headache, and preparation method thereof
CL2014000267A1 (es) Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion.
EP3137603A4 (en) A novel affinity matrix and devices for isolation and purification of rna and dna for point of care molecular devices
BR112014015753A8 (pt) derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção
EP3156055A4 (en) Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2013, OBSERVADAS AS CONDICOES LEGAIS.